Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$478K Sell
1,901
-5
-0.3% -$1.08K 0.1% 41
2026
Q1
$414K Buy
1,906
+2
+0.1% +$444 0.1% 42
2025
Q4
$420K Buy
1,904
+162
+9% +$36.9K 0.1% 43
2025
Q3
$403K Buy
1,742
+1
+0.1% +$204 0.1% 41
2025
Q2
$323K Sell
1,741
-3
-0.2% -$558 0.09% 44
2025
Q1
$365K Sell
1,744
-7
-0.4% -$1.36K 0.11% 40
2024
Q4
$311K Sell
1,751
-25
-1% -$4.6K 0.1% 42
2024
Q3
$351K Sell
1,776
-61
-3% -$11.4K 0.1% 40
2024
Q2
$315K Sell
1,837
-63
-3% -$10.4K 0.1% 41
2024
Q1
$346K Sell
1,900
-582
-23% -$100K 0.11% 42
2023
Q4
$385K Buy
2,482
+139
+6% +$20.3K 0.13% 35
2023
Q3
$349K Buy
2,343
+7
+0.3% +$1.03K 0.13% 33
2023
Q2
$315K Buy
2,336
+7
+0.3% +$1.03K 0.11% 33
2023
Q1
$371K Buy
2,329
+389
+20% +$59.5K 0.14% 31
2022
Q4
$314K Buy
1,940
+93
+5% +$14.3K 0.13% 32
2022
Q3
$248K Sell
1,847
-12
-0.6% -$1.72K 0.11% 30
2022
Q2
$285K Buy
1,859
+5
+0.3% +$764 0.12% 29
2022
Q1
$300K Buy
1,854
+1
+0.1% +$145 0.12% 26
2021
Q4
$264K Buy
+1,853
New +$219K 0.1% 30

Other funds holding ABBV

Whitcomb & Hess's ABBV Position: Q2 2026 in Review

Whitcomb & Hess reduced its AbbVie (ABBV) stake by 0.26% in Q2 2026, selling an estimated $1.08K and leaving 1,901 shares worth $478K. The position accounts for 0.1% of the portfolio, ranked #41.

Whitcomb & Hess first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 2,555 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Whitcomb & Hess held 1,901 shares of AbbVie worth $478K as of Q2 2026.
  • Whitcomb & Hess sold 5 AbbVie shares in Q2 2026, an estimated $1.08K.
  • AbbVie made up 0.1% of Whitcomb & Hess's portfolio in Q2 2026, its #41 holding.
  • Whitcomb & Hess first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 2,555 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Whitcomb & Hess's 13F filing for Q2 2026, filed 8 Jul 2026.